Abstract: A computer system stores biomolecular data in a database in a memory. The biomolecular database has a set of entities. Each entity stores attributes for a plurality of entries. At least one attribute is stored in an array. Data associated with an entry is stored at a location in the array. An entity offset designates the location of the data in the array. The same entity offset value is used to access data associated with a particular entry for all attributes within the entity.
Type:
Grant
Filed:
April 11, 2001
Date of Patent:
May 14, 2002
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Philippe E. Rigault, Anne L. Curtis, Richard D. Goold, David A. Hadley, Harold H. Hibbert, Tod M. Klingler, Robert E. Lagace, Laura L. Stuve, Michael G. Walker, Michael P. Wood
Abstract: Methods are provide for preparing cDNA corresponding to a mRNA. In the subject methods, a mRNA is first contacted with a mixture of primers under first strand cDNA synthesis conditions. The primer mixture contains primers that have at least 10 contiguous deoxythymidines, a double stranded restriction enzyme recognition sequence near one end and a non-polyA-complementary region near the other end, where the non-polyA-complementary region is -VV, -VTV, -VTTV, -VTTTV, and -VVVVV. The resultant cDNA is modified such that the polyT tail is substantially removed. The modified cDNA is then ligated into a vector. The subject methods find use in a variety of applications, and find particular use in the sequencing of DNA and in the synthesis of cDNA libraries.
Type:
Grant
Filed:
April 14, 2000
Date of Patent:
May 14, 2002
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Glenn K. Fu, Steven Starnes, Laura L. Stuve
Abstract: The present invention provides a human selenium-binding protein (HSEBP) and polynucleotides which identify and encode HSEBP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSEBP and a method for producing HSEBP. The invention also provides for agonists and antibodies specifically binding HSEBP, and their use in the prevention and treatment of diseases associated with expression of HSEBP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSEBP for the treatment of diseases associated with the expression of HSEBP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSEBP.
Abstract: The present invention provides novel human protein kinases (HPK) and polynucleotides which identify and encode HPK. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPK. The invention also provides for pharmaceutical compositions comprising HPK or antagonists of HPK, and antibodies which specifically bind HPK. Additionally, the invention provides antisense molecules to HPK for treatment or prevention of diseases associated with abnormal expression of HPK.
Type:
Application
Filed:
March 15, 2001
Publication date:
April 11, 2002
Applicant:
Incyte Pharmaceuticals, Inc.
Inventors:
Janice Au-Young, Karl J. Guegler, Phillip R. Hawkins
Abstract: The invention provides two human extracellular matrix proteins (ECMP) and polynucleotides which identify and encode ECMP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ECMP.
Type:
Application
Filed:
April 16, 2001
Publication date:
March 28, 2002
Applicant:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Neil C. Corley, Karl J. Guegler
Abstract: The present invention provides a human tumorigenesis protein (HTAP) and polynucleotides which identify and encode HTAP. In addition, the invention provides expression vectors and host cells, agonists, antibodies, and antagonists. The invention also provides methods for producing HTAP and for treating or preventing disorders associated with the expression of HTAP.
Abstract: The invention provides a human glutathione peroxidase (GPx6) and polynucleotides which identify and encode GPx6. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of GPx6.
Type:
Application
Filed:
March 16, 2001
Publication date:
March 14, 2002
Applicant:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Neil C. Corley, Chandra Patterson
Abstract: Novel mammalian phospholipase (PLA2) nucleotide sequences and low molecular weight (about 14 KD) amino acid sequences encoded thereby are disclosed. More particularly, a cloned human HPLA2 cDNA expressing HPLA2-10 and its cloned rat RPLA2 cDNA counterpart, expressing RPLA2-10, which are characterized as PLA2 Type IV, are disclosed. A second type of PLA2 cDNA, characterized as PLA2 Type III and exemplified by a rat PLA2 cDNA encoding RPLA2-8 and a partial human PLA2 nucleotide sequence encoding HPLA2-8, is disclosed. Expression of the cDNAs encode the two new types of PLA2 enzymes which have phospholipase activity. The novel PLA2s do not include disulfide bridges between cysteine amino acids 11 and 77 or elapid loops. However, the novel PLA2s may include amino acid COOH-terminal extensions which can vary in length.
Type:
Grant
Filed:
July 28, 1999
Date of Patent:
March 5, 2002
Assignees:
Incyte Pharmaceuticals, Inc.
Inventors:
Jay A. Tischfield, Jeffrey J. Seilhamer
Abstract: The present invention provides purified, corn seedling-derived polynucleotides (cdps) which encode corn seedling-derived polypeptides (CDPs). The invention also provides for the use of cdps or their complements, oligonucleotides, or fragments in methods for determining altered gene expression, to recover regulatory elements, and to follow inheritance of desirable characteristics through hybrid breeding programs. The invention further provides for vectors and host cells containing cdps for the expression of CDPs. The invention additionally provides for (i) use of isolated and purified CDPs to induce antibodies and to screen libraries of compounds and (ii) use of anti-CDP antibodies in diagnostic assays.
Type:
Application
Filed:
August 6, 2001
Publication date:
January 31, 2002
Applicant:
Incyte Pharmaceuticals, Inc.
Inventors:
Raghunath V. Lalgudi, Laura Y. Ito, Bradley K. Sherman
Abstract: The invention provides a human thyroid and pituitary membrane protein (TPMP) and polynucleotides which identify and encode TPMP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of TPMP.
Type:
Application
Filed:
May 7, 2001
Publication date:
January 24, 2002
Applicant:
Incyte Pharmaceuticals, Inc.
Inventors:
Preeti Lal, Neil C. Corley, Gina Gorgone
Abstract: The invention provides a human cyclic GMP phosphodiesterase (PDE9A) and polynucleotides which identify and encode PDE9A. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE9A.
Type:
Application
Filed:
March 8, 2001
Publication date:
January 17, 2002
Applicant:
Incyte Pharmaceuticals, Inc.
Inventors:
Douglas A. Fisher, Douglas H. Gooding, David Gray Streeter
Abstract: The present invention provides novel human cytokines (designated individually as NHC-1 and NHC-2, and collectively as NHC) and polynucleotides which identify and encode NHC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHC and a method for producing NHC. The invention also provides for use of NHC and agonists, antibodies, or antagonists specifically binding NHC, in the prevention and treatment of diseases associated with expression of NHC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHC for the treatment of diseases associated with the expression of NHC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHC.
Type:
Application
Filed:
February 12, 2001
Publication date:
January 3, 2002
Applicant:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Phillip R. Hawkins, Lynn E. Murry, Surya K. Goli
Abstract: Methods and compositions are provided for producing full-length cDNA libraries. In the subject methods, full length first strand cDNAs are isolated using a fusion protein of an eIF-4E domain and an eIF-4G domain separated by a flexible linker. Also provided is the novel fusion protein employed in the subject methods, as well as nucleic acids encoding, and host cells capable of expressing, the same. Finally, kits for use in practicing the subject methods are provided. The subject invention finds use in a variety of applications in which full-length CDNA libraries are employed.
Type:
Grant
Filed:
July 13, 1999
Date of Patent:
December 4, 2001
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Karl Guegler, Ruoying Tan, Michael J. Rose
Abstract: The present invention provides four NADH dehydrogenase subunits (designated individually as NDS-1, NDS-2, NDS-3, and NDS-4 and collectively as NDS) and polynucleotides which identify and encode NDS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NDS and a method for producing NDS. The invention also provides for use of NDS and agonists, antibodies, or antagonists specifically binding NDS, in the prevention and treatment of diseases associated with expression of NDS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NDS for the treatment of diseases associated with the expression of NDS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NDS.
Type:
Application
Filed:
November 29, 2000
Publication date:
November 15, 2001
Applicant:
Incyte Pharmaceuticals, Inc
Inventors:
Olga Bandman, Surya K. Goli, Jennifer L. Hillman
Abstract: The present invention is a computerized storage and retrieval system for genetic information and related annotated information. The data of the system is stored in a relational database which interfaces with public databases to allow analysis both within the database of the invention and between information within that database and external public databases. The sequence data is edited before entry into the system, and is stored in a curated, functional clustering organization. The information associated with the data is stored in an expression database that is linked to the storage of the sequence data.
Type:
Grant
Filed:
November 13, 1997
Date of Patent:
October 16, 2001
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Steve E. Lincoln, Tod M. Klingler, Janice Au-Young, Y. Tom Tang, Richard D. Goold, Ingrid E. Akerblom, Jeffrey J. Seilhamer, Phillip R. Hawkins, Lynn E. Murry, Angelo M. Delegeane, Wendy B. Levine, Jennifer L. Hillman, Surya K. Goli, Christina M. Altus, Olga Bandman, Samuel T. LaBrie, Purvi Shah
Abstract: The invention provides a human membrane spanning proteins (MSPs) and polynucleotides which identify and encode MSPs. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of MSPs.
Type:
Application
Filed:
March 30, 2001
Publication date:
September 27, 2001
Applicant:
Incyte Pharmaceuticals, Inc.
Inventors:
Y. Tom Tang, Olga Bandman, Preeti Lal, Jennifer L. Hillman, Henry Yue, Neil C. Corley, Karl J. Guegler, Matthew R. Kaser, Mariah R. Baughn, Purvi Shah
Abstract: The invention provides a human peroxisomal thioesterase (PxTE) and polynucleotides which identify and encode PxTE. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PxTE.
Type:
Application
Filed:
January 18, 2001
Publication date:
September 27, 2001
Applicant:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Purvi Shah, Neil C. Corley
Abstract: ? The invention provides an autoantigen-like protein (AUTOP) and polynucleotides which identify and encode AUTOP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of AUTOP.
Type:
Application
Filed:
January 10, 2001
Publication date:
August 23, 2001
Applicant:
Incyte Pharmaceuticals, Inc,
Inventors:
Preeti Lal, Neil C. Corley, Y. Tom Tang
Abstract: The present invention provides a human NADH-D protein subunit (NDS) and polynucleotides which encode NDS. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of NDS.
Type:
Grant
Filed:
December 9, 1998
Date of Patent:
August 21, 2001
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Purvi Shah, Preeti Lal
Abstract: The present invention provides a human calcium-binding protein (HCBP) and polynucleotides which identify and encode HCBP. The invention also provides expression vectors and host cells, agonists, antibodies, and antagonists. In addition, the invention provides methods for producing HCBP and for treating or preventing disorders associated with the expression of HCBP.